In vitro binding interaction of atorvastatin with calf thymus DNA: multispectroscopic, gel electrophoresis and molecular docking studies
Publication date: Available online 18 August 2018Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Zeinab Mirzaei-KalarAbstractThe interaction of atorvastatin with calf thymus DNA (CT-DNA) was investigated in vitro under simulated physiological conditions by using absorption and emission spectroscopy, viscosity measurements, gel electrophoresis and molecular docking studies. Analysis of UV-Visible absorbance spectra indicates the formation of complex between atorvastatin and CT-DNA, and obtained binding constant (Kb = 8.2×104 L. mol-1) is comparable to groove binder drugs. Slight increase of viscosity of CT-DNA demonstrated the groove binding mode. Hoechst 33258 and methylene blue (MB) displacement studies further confirmed such mode of atorvastatin interaction. Thermodynamic parameters ΔG, ΔH, and ΔS measurements were taken at different temperatures indicated that hydrophobic forces played main role in the binding process. Molecular docking provided detailed computational interaction of atorvastatin with CT-DNA which proved that atorvastatin binds to the groove of CT-DNA. Cleavage experiments showed that atorvastatin does not induce any cleavage under the experimental setup. Finally, all results indicated that atorvastatin interacts with CT-DNA via groove binding mode.Graphical abstract
After controversial guidelines were introduced, cholesterol levels are inching down and more Americans are taking much-needed statin drugs.
CONCLUSION: Dyslipidemia patients with pre-existing depression had increased risk for CVD. Future studies that determine CVD risk after management of depression among dyslipidemia patients are needed. PMID: 31701694 [PubMed - as supplied by publisher]
The 2013 American College of Cardiology and American Heart Association practice guidelines recommend physicians prescribe HMG-CoA reductase inhibitors (statins) to patients with high cholesterol and to patients with or at high risk for atherosclerotic cardiovascular disease, regardless of cholesterol levels1. According to the National Center for Health Statistics (NCHS), from 2011 to 2012, 1 in 4 adults ages 40 years and older were taking prescription cholesterol lowering medications, 93% of which were statins2.
Conclusion: Early rule out protocol is effective and safe.We refer interested readers to the following excellent reviews of high-sensitivity troponin implementation:Twerenbold, R. et al.JACC70 (8): 996 –1012.https://doi.org/10.1016/j.jacc.2017.07.718.Yader S. et al. 2016. Am J Med 129 (4): 354 –65.https://doi.org/10.1016/j.amjmed.2015.12.005.Response to the 2nd “Myth-busting” articleInterestingly, on Nov 5, Dr. Spiegel publishedanother “Myths in EM” piece in EM News: “Is hs-cTnT Worth the Downstream Testing?. The piece assesses a new randomized trial of the Roche hs -cTnT...
CONCLUSIONS: No association between ApoB/apoA1 ratio and CVE was found at the baseline visit of patients with RA from the CARMA study. PMID: 31694752 [PubMed - as supplied by publisher]
Words that harm, statins, thyroid replacement, and the ISCHEMIA trial are the topics discussed by Dr John Mandrola in this week ’ s podcast.theheart.org on Medscape
What have we learned about the effects of long-term statin therapy among this age group? Is it beneficial?Journal of the American Geriatrics Society
In patients with diabetes, where cardiovascular morbidity is highly prevalent, recent cardiovascular outcomes trials have identified therapies in the modern glucagon-like peptide 1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) classes that significantly reduce cardiovascular events. A number of drugs in both classes have demonstrated reductions in the risk of the composite outcome of major adverse cardiovascular events (myocardial infarction, stroke, and cardiovascular death). In addition, SGLT2i drugs have a substantial impact on hospitalization for heart failure. Because GLP-1RA and SGL...
Conclusions. Our data suggests that hsa-miR-24-3p might have an effect on CYP4F2 activity during atherosclerosis. PMID: 31694408 [PubMed - as supplied by publisher]
Evidence from observational studies have found a relationship between serum cholesterol and diabetic retinopathy (DR). Apart of the assumption that cholesterolemic control has benefits for patients with diabet...